This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS : Primary: + To assess the safety of escalating doses of CP-675,206 when administered in combination with DC vaccination in patients with advanced melanoma. + To assess the biological activity and immune effects of CP-675,206 in combination with dendritic cell (DC) vaccination, as measured by enzyme linked immunospot (ELISPOT) and tetramer assays (supporting proof-of-mechanism). Secondary: + To explore whether the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) genotype influences the safety and/or immune response of patients treated with CP-675,206. + To document any preliminary evidence of efficacy as measured by clinical benefit rate. Tertiary (exploratory): + Determinant spreading. + Lowest dose necessary for obtaining a difference pre and post treatment in the MART-127-35-specific cells.
Showing the most recent 10 out of 1085 publications